DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
We previously described PASD1 as a new cancer testis antigen in multiple myeloma (MM) that is retained post-therapy, suggesting the use of vaccination strategies to induce anti-PASD1 immunity in a setting of minimal residual disease. We have focused on DNA fusion gene vaccines, coupling fragment C d...
Principais autores: | Joseph-Pietras, D, Gao, Y, Zojer, N, Ait-Tahar, K, Banham, A, Pulford, K, Rice, J, Savelyeva, N, Sahota, S |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2010
|
Registros relacionados
-
PASD1 is a potential multiple myeloma-associated antigen.
por: Sahota, S, et al.
Publicado em: (2006) -
Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
por: Campbell, A, et al.
Publicado em: (2010) -
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
por: Cooper, C, et al.
Publicado em: (2006) -
Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
por: Ait-Tahar, K, et al.
Publicado em: (2009) -
Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
por: Ait-Tahar, K, et al.
Publicado em: (2009)